#NewAseBioMember | “This partnership gives us the possibility to establish key contacts and collaborate with leading companies in the sector”
Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal.

AseBio. What does your company's work bring to the table and what is its strength?
Raquel Márquez Duro. Kirsch Pharma is a leading global supplier of raw materials and blends for the pharmaceutical, biopharmaceutical, nutritional, veterinary, and cosmetic sectors. Our portfolio includes APIs, excipients, and active ingredients. With a track record of more than thirty years in the market, we have a network of qualified and reliable suppliers, which allows us to offer customised and high-quality solutions to our customers.
Our subsidiary in Spain, Kirsch Pharma España, was established in 1991 and is GDP (Good Distribution Practices) certified to guarantee the integrity of the products we distribute. We are in Alcalá de Henares, where we have an office and warehouse of 1700 square meters, including a temperature-controlled chamber, and in Barcelona, where we have a sales office.
As part of the German-based Kirsch Pharma Group, we have a global presence with offices and warehouses strategically located in South Africa, Singapore, China, and Australia. This allows us to offer global coverage and a rapid response to our customers' needs.
Today, most pharmaceutical laboratories in Spain rely on us because of our high standards of quality, customer service and knowledge of the Life-Sciences market. We are committed to customer satisfaction and strive to offer customised solutions, from the very beginning of each project, including compliance with requested specifications, documentation, specialised packaging, physical modification, and other additional services.
AseBio. What is AseBio for you?
Raquel Márquez Duro. The collaboration with ASEBIO represents a strategic opportunity to strengthen Kirsch Pharma's presence and reputation in the Spanish biopharmaceutical market. This partnership gives us the possibility to establish key contacts and collaborate with leading companies in the sector, which will allow us to position ourselves strongly in a highly competitive market.
Our current focus is on developing and growing our business in the biopharmaceutical sector, and membership of ASEBIO will provide us with the necessary impetus to achieve greater visibility and recognition in the industry. This strategic partnership will give us access to resources, knowledge and opportunities that will help us consolidate our presence and advance our commercial objectives in the biopharmaceutical sector.
AseBio. When did you first hear about AseBio?
Raquel Márquez Duro. Before entering such a dynamic and competitive market as the biopharmaceutical sector in Spain, it is essential to carry out an exhaustive market study. This analysis allows us to identify potential customers, evaluate the competition and get to know the relevant organisations and institutions in the sector. During our research, we discovered the importance of AseBio, a key organisation that brings together numerous companies in the biopharmaceutical sector. Its role as a meeting and collaboration point between companies in the sector has led us to recognise its strategic value in our incursion into this constantly evolving market.
AseBio. What do you expect from being part of an association like AseBio?
Raquel Márquez Duro. Being part of an association such as ASEBIO, our expectations are diverse and strategic:
- Recognition and Collaborations: We hope to increase our visibility and reputation in the biopharmaceutical and biotechnology sector, establishing key contacts and exploring possible collaborations with potential customers.
- Positioning as a Quality Supplier: We seek to consolidate our image as a manufacturer and supplier of high-quality raw materials in the biopharmaceutical sector, highlighting our commitment to excellence and reliability in our products.
- Updating and Market Knowledge: We are interested in keeping up to date with the latest trends and developments in the sector, which will allow us to proactively adapt to the changes and opportunities that arise in the biopharmaceutical industry. Keeping up to date with trends and technological advances is essential to maintain our competitiveness and relevance in a constantly evolving environment.
AseBio. What is the biggest challenge facing the biotech sector (or your company)?
Raquel Márquez Duro. For us, the biggest challenge in the biotech sector today is the need to maintain high quality standards in the products offered. In a highly competitive environment such as the biopharmaceutical/biotech sector, product quality is essential, especially considering the use of products.
The requirement to meet precise specifications from customers presents an additional challenge, as any variation in product quality or composition can significantly impact the drug manufacturing process. This stringency in quality standards sometimes hinders customers' flexibility to switch suppliers, which can limit opportunities for growth and expansion in the market.
In addition, the raw material approval process is often lengthy and complex, adding an additional layer of challenge for companies in the sector. The need to comply with regulatory and quality requirements involves a meticulous and detailed process that can slow down the introduction of new products or suppliers to the market.
In summary, the biggest challenge for the biotech sector is to maintain excellence in product quality, meet customer demands and overcome the hurdles associated with the raw material approval process, all in a highly competitive and regulated environment such as the biopharmaceutical/biotech sector.